• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

高浓度单克隆抗体 IgG1 和 IgG4 亚型蛋白制剂的黏度 - 通过蛋白-蛋白相互作用测量预测黏度。

Viscosity of high concentration protein formulations of monoclonal antibodies of the IgG1 and IgG4 subclass - prediction of viscosity through protein-protein interaction measurements.

机构信息

Section for Biologics, Department of Pharmacy, Faculty of Health and Medical Sciences, University of Copenhagen, Universitetsparken 2, Copenhagen, Denmark.

出版信息

Eur J Pharm Sci. 2013 Jun 14;49(3):400-10. doi: 10.1016/j.ejps.2013.04.019. Epub 2013 Apr 26.

DOI:10.1016/j.ejps.2013.04.019
PMID:23624326
Abstract

The purpose of this work was to explore the relation between protein-protein interactions (PPIs) and solution viscosity at high protein concentration using three monoclonal antibodies (mAbs), two of the IgG4 subclass and one of the IgG1 subclass. A range of methods was used to quantify the PPI either at low concentration (interaction parameter (kD) obtained from dynamic light scattering, DLS) or at high concentration (solution storage modulus (G') from ultrasonic shear rheology). We also developed a novel method for the determination of PPI using the apparent radius of the protein at either low or high protein concentration determined using DLS. The PPI measurements were correlated with solution viscosity (measured by DLS using polystyrene nanospheres and ultrasonic shear rheology) as a function of pH (4-9) and ionic strength (10, 50 and 150 mM). Our measurements showed that the highest solution viscosity was observed under conditions with the most negative kD, the highest apparent radius and the lowest net charge. An increase in ionic strength resulted in a change in the nature of the PPI at low pH from repulsive to attractive. In the neutral to alkaline pH region the mAbs behaved differently with respect to increase in ionic strength. Two mAbs (A and B) showed little or no effect of increasing ionic strength, whereas mAb-C showed a remarkable decrease in attractive PPI and viscosity. Previous studies have mainly investigated mAbs of the IgG₁ and IgG₂ subclass. We show here, for the first time, that mAbs of the IgG₄ subclass behave similar as the other subclasses. By comparison of the three tested mAbs with mAbs investigated in other studies a clear linear trend emerges between the pH of strongest attractive PPI and highest solution viscosity. The determination of PPI using either kD or apparent radius is thus a useful prediction tool in the determination of solution conditions that favors low solution viscosity at high protein concentration of therapeutically used mAb molecules. The novel methodology using apparent radius is a simple and rapid alternative to determine relative PPI directly under formulation conditions. The method can potentially serve as a high-throughput screening tool in formulation development.

摘要

这项工作的目的是使用三种单克隆抗体(mAbs)——两种 IgG4 亚类和一种 IgG1 亚类——探索蛋白质-蛋白质相互作用(PPIs)与高浓度蛋白质溶液粘度之间的关系。我们使用了一系列方法来定量测定低浓度下的 PPI(通过动态光散射,DLS 获得的相互作用参数(kD))或高浓度下的 PPI(通过超声剪切流变学获得的溶液储能模量(G'))。我们还开发了一种新的方法,用于通过 DLS 确定蛋白质的表观半径来测定低浓度或高浓度下的 PPI。将 PPI 测量值与溶液粘度(使用聚苯乙烯纳米球通过 DLS 测量和超声剪切流变学测量)相关联,作为 pH 值(4-9)和离子强度(10、50 和 150 mM)的函数。我们的测量结果表明,在具有最负 kD、最高表观半径和最低净电荷的条件下,观察到最高的溶液粘度。随着离子强度的增加,在低 pH 值下,PPI 的性质从排斥变为吸引。在中性到碱性 pH 区域,mAbs 对离子强度增加的反应不同。两种 mAb(A 和 B)的离子强度增加几乎没有或没有影响,而 mAb-C 的吸引性 PPI 和粘度则显著降低。以前的研究主要集中在 IgG₁和 IgG₂亚类的 mAb 上。我们在这里首次表明,IgG₄ 亚类的 mAb 表现与其他亚类相似。通过比较三种测试的 mAb 与其他研究中测试的 mAb,可以清楚地看出,最强吸引力 PPI 的 pH 值与最高溶液粘度之间存在明显的线性趋势。因此,使用 kD 或表观半径测定 PPI 是一种有用的预测工具,可用于确定在高浓度治疗性 mAb 分子下有利于低溶液粘度的溶液条件。使用表观半径的新方法是在配方条件下直接测定相对 PPI 的简单快速替代方法。该方法有可能成为配方开发中的高通量筛选工具。

相似文献

1
Viscosity of high concentration protein formulations of monoclonal antibodies of the IgG1 and IgG4 subclass - prediction of viscosity through protein-protein interaction measurements.高浓度单克隆抗体 IgG1 和 IgG4 亚型蛋白制剂的黏度 - 通过蛋白-蛋白相互作用测量预测黏度。
Eur J Pharm Sci. 2013 Jun 14;49(3):400-10. doi: 10.1016/j.ejps.2013.04.019. Epub 2013 Apr 26.
2
Ultrasonic storage modulus as a novel parameter for analyzing protein-protein interactions in high protein concentration solutions: correlation with static and dynamic light scattering measurements.超声储能模量作为分析高蛋白浓度溶液中蛋白质-蛋白质相互作用的新参数:与静态和动态光散射测量的相关性
Biophys J. 2007 Jan 1;92(1):234-44. doi: 10.1529/biophysj.106.095174. Epub 2006 Oct 6.
3
Studying Excipient Modulated Physical Stability and Viscosity of Monoclonal Antibody Formulations Using Small-Angle Scattering.利用小角散射研究赋形剂调节的单克隆抗体制剂的物理稳定性和黏度。
Mol Pharm. 2019 Oct 7;16(10):4319-4338. doi: 10.1021/acs.molpharmaceut.9b00687. Epub 2019 Sep 24.
4
Specific interactions in high concentration antibody solutions resulting in high viscosity.高浓度抗体溶液中的特定相互作用导致高粘度。
J Pharm Sci. 2010 Mar;99(3):1152-68. doi: 10.1002/jps.21898.
5
Stability of monoclonal antibodies at high-concentration: head-to-head comparison of the IgG1 and IgG4 subclass.高浓度下单克隆抗体的稳定性:IgG1和IgG4亚类的直接比较
J Pharm Sci. 2014 Jan;103(1):115-27. doi: 10.1002/jps.23788. Epub 2013 Nov 26.
6
Factors affecting the viscosity in high concentration solutions of different monoclonal antibodies.不同单克隆抗体高浓度溶液黏度的影响因素。
J Pharm Sci. 2010 Dec;99(12):4812-29. doi: 10.1002/jps.22190.
7
How Well Do Low- and High-Concentration Protein Interactions Predict Solution Viscosities of Monoclonal Antibodies?低浓度和高浓度蛋白相互作用在多大程度上可以预测单克隆抗体的溶液黏度?
J Pharm Sci. 2019 Jan;108(1):142-154. doi: 10.1016/j.xphs.2018.07.007. Epub 2018 Jul 12.
8
Intermolecular interactions of IgG1 monoclonal antibodies at high concentrations characterized by light scattering.利用光散射技术研究高浓度 IgG1 单克隆抗体的分子间相互作用。
J Phys Chem B. 2010 Oct 14;114(40):12948-57. doi: 10.1021/jp1028646.
9
Ultrasonic rheology of a monoclonal antibody (IgG2) solution: implications for physical stability of proteins in high concentration formulations.单克隆抗体(IgG2)溶液的超声流变学:对高浓度制剂中蛋白质物理稳定性的影响
J Pharm Sci. 2007 Dec;96(12):3181-95. doi: 10.1002/jps.20970.
10
Differences in human IgG1 and IgG4 S228P monoclonal antibodies viscosity and self-interactions: Experimental assessment and computational predictions of domain interactions.人源 IgG1 和 IgG4 S228P 单克隆抗体的黏度和自身相互作用的差异:结构域相互作用的实验评估和计算预测。
MAbs. 2021 Jan-Dec;13(1):1991256. doi: 10.1080/19420862.2021.1991256.

引用本文的文献

1
An Underlying Cause and Solution to the Poor Size Exclusion Chromatography Performance of Antibody-Drug Conjugates.抗体药物偶联物尺寸排阻色谱性能不佳的潜在原因及解决方案
Pharm Res. 2024 Dec;41(12):2299-2317. doi: 10.1007/s11095-024-03796-x. Epub 2024 Dec 13.
2
Poly(glutamic acid)-Based Viscosity Reducers for Concentrated Formulations of a Monoclonal IgG Antibody.基于聚谷氨酸的粘度降低剂用于单克隆 IgG 抗体的高浓度制剂。
Mol Pharm. 2024 Feb 5;21(2):982-991. doi: 10.1021/acs.molpharmaceut.3c01159. Epub 2024 Jan 19.
3
The role of acidification of the medium on the erythrocyte agglutinating and adsorbing properties of blood group-specific monoclonal antibodies.
培养基酸化对血型特异性单克隆抗体的红细胞凝集和吸附特性的作用。
Korean J Transplant. 2023 Sep 30;37(3):189-196. doi: 10.4285/kjt.23.0033.
4
A systematic review of commercial high concentration antibody drug products approved in the US: formulation composition, dosage form design and primary packaging considerations.美国批准的商业化高浓度抗体药物产品的系统评价:制剂组成、剂型设计和初级包装考虑因素。
MAbs. 2023 Jan-Dec;15(1):2205540. doi: 10.1080/19420862.2023.2205540.
5
Using Cluster Theory to Calculate the Experimental Structure Factors of Antibody Solutions.运用团簇理论计算抗体溶液的实验结构因子。
Mol Pharm. 2023 May 1;20(5):2738-2753. doi: 10.1021/acs.molpharmaceut.3c00191. Epub 2023 Apr 17.
6
Trends in industrialization of biotherapeutics: a survey of product characteristics of 89 antibody-based biotherapeutics.生物疗法的工业化趋势:89 种基于抗体的生物疗法产品特征调查。
MAbs. 2023 Jan-Dec;15(1):2191301. doi: 10.1080/19420862.2023.2191301.
7
Predictive modeling of concentration-dependent viscosity behavior of monoclonal antibody solutions using artificial neural networks.使用人工神经网络预测单克隆抗体溶液的浓度依赖性粘度行为。
MAbs. 2023 Jan-Dec;15(1):2169440. doi: 10.1080/19420862.2023.2169440.
8
Developability assessment at early-stage discovery to enable development of antibody-derived therapeutics.在早期发现阶段进行可开发性评估,以推动抗体衍生疗法的开发。
Antib Ther. 2022 Nov 11;6(1):13-29. doi: 10.1093/abt/tbac029. eCollection 2023 Jan.
9
Structure-Based Optimization of Antibody-Based Biotherapeutics for Improved Developability: A Practical Guide for Molecular Modelers.基于结构的抗体类生物治疗药物开发性优化:分子建模师实用指南。
Methods Mol Biol. 2023;2552:219-235. doi: 10.1007/978-1-0716-2609-2_11.
10
Effects of Monovalent Salt on Protein-Protein Interactions of Dilute and Concentrated Monoclonal Antibody Formulations.单价盐对稀释和浓缩单克隆抗体制剂中蛋白质-蛋白质相互作用的影响。
Antibodies (Basel). 2022 Mar 31;11(2):24. doi: 10.3390/antib11020024.